NCT02306291View on ClinicalTrials.gov

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

May 31, 2018

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

GMI-1271

E-selectin antagonist

DRUG

Mitoxantrone

induction chemotherapy

DRUG

Etoposide

induction chemotherapy

DRUG

Cytarabine

induction chemotherapy

DRUG

Idarubicin

induction chemotherapy

Trial Locations (8)

14642

University of Rochester, Rochester

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor, Ann Arbor

95817

University of California, Davis Comprehensive Cancer Center, Sacramento

98109

University of Washington, Seattle

02115

Dana Farber Cancer Institute, Boston

Unknown

Princess Alexandra Hospital, Brisbane

University Hospital Galway, Galway

All Listed Sponsors

lead

GlycoMimetics Incorporated

INDUSTRY

NCT02306291 - Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | Biotech Hunter | Biotech Hunter